ALX Oncology's Evorpacept Combination Achieves 92% Complete Response Rate in Frontline Indolent Non-Hodgkin Lymphoma Trial
核心洞察
ALX Oncology's evorpacept combined with rituximab and lenalidomide achieved a 92% complete response rate in previously untreated indolent non-Hodgkin lymphoma (搜索) patients, nearly doubling the historical 50% rate for standard therapy alone.
The Phase 2 investigator-sponsored trial enrolled 24 patients and demonstrated 100% overall response rate with well-tolerated safety profile in the frontline treatment setting.
One-year progression-free survival reached 91% and overall survival was 100%, supporting evorpacept's potential as a cornerstone immuno-oncology therapy targeting CD47 (搜索).
ALX Oncology announced positive results from a Phase 2 investigator-sponsored trial evaluating evorpacept in combination with standard-of-care rituximab and lenalidomide for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). The combination achieved a 92% complete response rate in previously untreated patients, comparing favorably to the approximate 50% historical complete response rate for rituximab and lenalidomide alone.
The data was presented at the American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida, demonstrating that the addition of evorpacept to standard therapy provides impressive anti-tumor activity in the frontline treatment setting while maintaining a well-tolerated safety profile.
Trial Design and Patient Population
The clinical trial, conducted by Dr. Paolo Strati, Associate Professor of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, enrolled 24 patients with previously untreated iNHL. The patient population included 14 patients with follicular lymphoma (搜索) and 10 patients with marginal zone lymphoma (搜索), all with high tumor burden disease.
The primary objective was to achieve a complete response rate above 80% with evorpacept added to the rituximab and lenalidomide (R2) regimen, compared to the historical R2 complete response rate of 50%.
Efficacy Results
The trial met its primary endpoint with remarkable efficacy outcomes. Among the 24 enrolled patients, 92% achieved a complete response and 8% achieved a partial response, resulting in a 100% overall response rate. The one-year progression-free survival rate was 91%, and the one-year overall survival rate was 100%.
"We are excited to see the results of this Phase 2 study in frontline indolent non-Hodgkin lymphoma (搜索) patients, where the addition of evorpacept added a meaningful benefit over the historical data for the standard-of-care regimen of rituximab and lenalidomide," said Jason Lettmann, Chief Executive Officer at ALX Oncology.
Mechanism of Action and Clinical Rationale
The combination leverages evorpacept's mechanism of blocking CD47 (搜索), which is highly expressed in non-Hodgkin lymphoma. According to Lettmann, this data supports the relevance of blocking CD47 in the presence of an anti-cancer antibody like rituximab to allow for the destruction of cancer cells.
Dr. Strati pursued this frontline study after observing promising activity using the same combination in the relapsed refractory setting, which was previously published. The current results demonstrate that this efficacy can be replicated in the frontline setting.
Safety and Tolerability
The investigators found the addition of evorpacept to R2 to be a well-tolerated frontline non-chemotherapy regimen for patients with iNHL. The combination provides an alternative to traditional chemotherapy approaches while maintaining high efficacy rates.
Future Directions
While longer follow-up data matures, the investigators plan to evaluate minimal residual disease (MRD) eradication rates with this novel regimen. ALX Oncology anticipates longer-term follow-up and MRD evaluation from this study to further characterize the durability of responses.
The company's lead therapeutic candidate, evorpacept, is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications and has demonstrated potential to serve as a cornerstone therapy for immuno-oncology applications.